$1.20
+0.00 (+0.00%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SYBX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 3 with posted results
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)NCT05764239results2024-06-20Mean Percent Change From DEP Baseline in Blood Phenylalanine (Phe) Level at Week 3 of iTD During the DEPRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Based on a review of interim data from participants in the dose-escalation phase, it was determined that the study was unlikely to meet the primary endpoint. | Drug: SYNB1934v1, Placebo | Phenylketonuria | 35 | 2024-03-15actual | 2024-06-20 |
| Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric HyperoxaluriaNCT04629170Number of Subjects With Treatment-Emergent Adverse EventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: SYNB8802, Placebo | Healthy, Enteric Hyperoxaluria | 77 | 2023-01-17actual | 2024-03-08 |
| Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel SyndromeNCT05377112Safety and tolerability of SYNB8802v1, as assessed by measuring of vital signsRandomized · Double-masked · Treatment | Early Phase 1 | Completed | Drug: SYNB8802v1 · Other: Placebo | Enteric Hyperoxaluria | 11 | 2022-12-07actual | 2023-03-17 |
| Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult VolunteersNCT05462132Number of participants with abnormal laboratory values and/or adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: SYNB1353 | Homocystinuria | 31 | 2022-11-27actual | 2023-03-17 |
| Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With PhenylketonuriaNCT04534842Changes from baseline in labeled Phe (D5-Phe) in plasmaNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: SYNB1618, SYNB1934 | Phenylketonuria | 20 | 2022-10-07actual | 2022-10-17 |
| Safety and Tolerability of SYNB1934 in Healthy Adult VolunteersNCT04984525Number of Subjects With Treatment-Emergent Adverse EventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: SYNB1934, SYNB1618 | Healthy | 106 | 2021-12-10actual | 2022-05-18 |
| Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult ParticipantsNCT04167137results2024-05-03Number of Participants With Dose-limiting ToxicityNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Business reasons | Drug: SYNB1891, Atezolizumab | Metastatic Solid Neoplasm, Lymphoma | 32 | 2021-12-09actual | 2024-05-03 |
| Safety, Tolerability and Pharmacodynamics of SYNB1020NCT03447730results2020-10-14Number of Participants With Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Interim futility analyses identified a lack of SYNB1020 efficacy. | Drug: SYNB1020 · Other: Placebo | Cirrhosis | 23 | 2019-07-19actual | 2021-05-13 |
| Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With PhenylketonuriaNCT03516487Number of Subjects With Treatment-Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: SYNB1618, Placebo | Phenylketonuria, Healthy | 70 | 2019-06-21actual | 2021-05-13 |
| Safety and Tolerability of SYNB1020-CP-001NCT03179878Incidence of Treatment-Emergent Adverse Events, Laboratory Assessments and ECGs to measure Safety and Tolerability of SYNB1020Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Placebo, SYNB1020 | Healthy Volunteer, Urea Cycle Disorder | 52 | 2017-11-02actual | 2021-05-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19